Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery

• Status: Completed
• Trial end date: 2021-02-05
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective pilot study in which the effects of ascorbic acid administration are investigated in adult patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass (CPB). Ascorbic acid (Vitamin C) is an essential cofactor in the biosynthesis of catecholamines, and critically ill patients are known to be ascorbate-deficient. In addition, cardiopulmonary bypass (CPB) decreases ascorbic acid concentrations. Cardiac vasoplegia is the loss of vascular tone despite adequate volume status and cardiac output, occurring commonly in patients after CPB. This necessitates the administration of vasopressors and alternative agents which can have deleterious effects. The administration of ascorbic acid to cardiac surgical patients may improve microcirculatory function, enhance endogenous catecholamine levels and decrease the need for exogenous vasopressor support.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Ascorbic Acid

Criteria

Inclusion criteria:

• 18 years of age or older

• Undergoing cardiac surgery with the use of cardiopulmonary bypass

• Undergoing myectomy or valve replacement/repair

Exclusion criteria:

• Coronary artery bypass grafting (CABG)

• Circulatory arrest

• Active infection or sepsis

• Severe hepatic disease or ascites

• Pre-operative renal dysfunction requiring dialysis

• Pre-operative midodrine

• Pre-operative oral or intravenous steroid use